Exelixis, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Exelixis, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 7.1 times. Higher than 91% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$127Over the last 3 years, every $100 of reported profit came with $127 of operating cash.
Lower than 66% of Healthcare companies in United States.
Self-Funding Ratio
7.1×Over the last 3 years its own operating cash covered its investment spending (capex) 7.1 times.
Higher than 91% of Healthcare companies in United States.
Cash Locked Ratio
$12For every $100 of sales, $12 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $13 tied up three years earlier.
Less money tied up than 76% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$85Sales grew 44% in 3 years; of every extra $100 of sales, $85 became extra profit.
Higher than 79% of Healthcare companies in United States.
Asset Productivity Ratio
+44% / -7%In 3 years sales changed by +44% while total assets changed by -7%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Lower than 56% of Healthcare companies in United States.
Tangible Assets Ratio
98%Of every $100 the company owns, $98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 83% of Healthcare companies in United States.
Tangible Net Worth Ratio
97%Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 85% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Exelixis, Inc. owes $0.26 for every $1 it owns. Net profit rose 50% in the year to Dec 2025, and grew 63% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
20.6Investors pay $20.6 for every $1 of Exelixis, Inc.'s yearly profit, lower than 63% of Healthcare companies in United States.
P/B ratio
8.78The share price is 8.78 times Exelixis, Inc.'s book value per share, higher than 84% of Healthcare companies in United States.
Market cap
$16.2 BThe total market value of all of Exelixis, Inc.'s shares at today's price (share price × number of shares), larger than 93% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$1.8 BWhat Exelixis, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.44Net worth divided by the number of shares. The share price of $65.31 is 8.8 times this, which is the P/B above.
Return on equity (ROE)
44.4%Exelixis, Inc. earned 44.4% on its shareholders' money over the last year, higher than 96% of Healthcare companies in United States.
Owes vs Owns
0.26×Exelixis, Inc. owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Dividend yield
NoneExelixis, Inc. does not currently pay a dividend.
Revenue growth
+7%Revenue rose 7% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Profit growth
+50%Net profit rose 50% in the year to Dec 2025, and grew 63% a year on average over 3 years.
Profit margin
33.7%Exelixis, Inc. keeps $34 of every $100 of revenue as net profit.
Cash quality
1.1×Cash from Exelixis, Inc.'s business was 1.1× its reported profit in the year to Dec 2025 — its profit turned into cash.
Cash vs debt
Net cashExelixis, Inc. held $886 M more cash than debt (net cash) at Dec 2025.
Questions
What is Exelixis, Inc.'s P/E ratio?
Investors pay $20.6 for every $1 of Exelixis, Inc.'s yearly profit, lower than 63% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Exelixis, Inc.: $16.2 B ÷ $1.8 B (30 Jun 2026) = 8.8.
What is Exelixis, Inc.'s return on equity?
Exelixis, Inc. earned 44.4% on its shareholders' money over the last year, higher than 96% of Healthcare companies in United States.
How much does Exelixis, Inc. owe compared with what it owns?
Exelixis, Inc. owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Does Exelixis, Inc. pay a dividend?
No. Exelixis, Inc. does not currently pay a dividend.
Is Exelixis, Inc.'s revenue growing?
Revenue rose 7% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.